tapebrief
VTRS · Q4 2025
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

VTRS · Q1 2025 Earnings

Viatris

Reported May 7, 2026

30-second summary

SENTIMENT: Cautiously constructive Viatris delivered Q1 2026 revenue of $3.52B (+8% reported / +3% operational YoY) and adjusted EPS of $0.59 (+18% reported / +14% operational), with adjusted EBITDA of $1.05B (+14% reported / +10% operational). Management reaffirmed every line of FY2026 guidance and continues to expect more than $2.5B of cash available for deployment in 2026. The lap of last year's $2.9B Q1 2025 goodwill impairment flips GAAP optics from a $3.0B loss to $176M net earnings. The operational beat is real; the Nashik fire write-off and the tariff disclosure gap carried over from prior guidance are the offsets.

Headline numbers

EPS

Q1 FY2025

$0.59

+18.0% vs est.

Revenue

Q1 FY2025

$3.52B

+8.0% YoY

+4.7% vs est.

Gross margin

Q1 FY2025

32.9%

Free cash flow

Q1 FY2025

$0.35B

Operating margin

Q1 FY2025

-2.3%

Key financials

Q1 FY2025
MetricQ1 FY2025YoYQ4 FY2025QoQ
Revenue$3.52B+8.0%$3.70B-4.9%
EPS$0.59—$0.57+3.5%
Gross margin32.9%—31.0%+190bps
Operating margin-2.3%—-5.2%+290bps
Free cash flow$0.35B—$0.62B-43.8%

Guidance

Viatris reaffirmed full-year FY2026 guidance across all major metrics (revenue, EPS, EBITDA, FCF) with Q1 results beating consensus on both revenue and adjusted EPS.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

New guidance

MetricPeriodGuideYoY
Cash Available for DeploymentFY2026More than $2.5 billion—

Reaffirmed unchanged this quarter: Revenue ($14,450 - $14,950 million, midpoint $14,700 million), Adjusted EPS ($2.33 - $2.47, midpoint $2.40), Adjusted EBITDA ($4,150 - $4,450 million, midpoint $4,300 million), Free Cash Flow (Excluding Transaction-related and Restructuring-related Costs) ($1,950 - $2,350 million, midpoint $2,150 million), U.S. GAAP Net Cash Provided by Operating Activities ($1,700 - $2,000 million, midpoint $1,850 million), New Product Revenues ($450 - $550 million)

Segment KPIs

Q1 FY2025
SegmentQ1 FY2025YoY
Brands$2.333B+4.0%
Generics$1.177B+1.0%

Other KPIs

Q1 FY2025
SegmentQ1 FY2025YoY
Developed Markets$2.021B+1.0%
Greater China$0.68B+18.0%
JANZ$0.273B-2.0%
Emerging Markets$0.535B—
Adjusted EBITDA$1,049.5 million—
Adjusted Gross Margin56.0%—
Adjusted EPS (Operational Growth)$0.59—
New Product Revenues$71 million—
Free Cash Flow (ex. Transaction/Restructuring)$459 million—
Adjusted R&D as % of Revenue7%—
Adjusted SG&A as % of Revenue22%—
Operating Cash Flow$388.3 million—

Management tone

The framing is "strong start, deliver on full-year guide." CEO Scott Smith: "We delivered a strong first quarter, reflecting disciplined execution across our global businesses... Our performance reinforces the growth trajectory we outlined at our Investor Event in March... we believe we are well positioned to deliver on our full-year guidance, and we remain focused on building a more durable, higher-quality growth profile for Viatris."

The Nashik fire is a new, quantified cost-of-sales item. The Q1 2026 reconciliation includes a $71.9M write-off of inventory and fixed assets damaged in the fire at the Nashik manufacturing facility — a fresh facility-level disruption. This sits inside adjusted reconciliations as a special item but is a real cash and operational event.

Pipeline cadence is delivering. The March 2026 Effexor approval in Japan for generalized anxiety disorder is now a launch. Phase 3 data from the low-dose estrogen patch and MR-141 (presbyopia) were presented at ACOG (May 1–3, 2026) and ASCRS (April 10–13, 2026), keeping the innovative pipeline on the disclosure cadence outlined at the March Investor Event.

Recurring themes management leaned on this quarter:

Indoor facility remediation and lenalidomide revenue loss permanenceTariff exposure and manufacturing mitigation strategiesPipeline acceleration with three positive Phase III readouts in 2025Non-opioid acute pain treatment opportunity positioningBase business resilience despite macro uncertainty and geopolitical volatilityDisciplined capital allocation with near-term asset focus

Risks management surfaced:

Tariffs on pharmaceuticals with unquantified but material financial impactSupply chain disruptions affecting patient access globallyIndoor facility impact extending partially into 2026 with no lenalidomide recoveryGeopolitical and economic uncertainty driving goodwill impairmentFDA inspection outcomes at Nashik facility remain pending classification

What to watch into next quarter

Tariff impact quantification. The reaffirmed guidance does not include any quantified tariff effect, and forward-looking risk language flags it as an unresolved exposure. Watch Q2 print for either a specific dollar bracket or a formal addition to guidance assumptions.

New product revenue Q2 step-up. Q1 was $71M. A Q2 print below $100M makes the $450–550M FY range mathematically harder; the iron sucrose, octreotide, and liraglutide launches are the gating items.

Nashik fire follow-through. The $71.9M Q1 inventory/fixed-asset write-off is the first cost. Watch for any extension into supply disruption, customer penalties, or insurance recovery disclosure in Q2.

Greater China sustainability at +18% operational. The segment is increasingly load-bearing for the consolidated growth print. If Q2 reverts to mid-single-digits, the consolidated growth math gets tighter.

Buyback pace and capital deployment. ">$2.5B cash available for deployment" was reaffirmed. The Q2 repurchase pace and any BD execution against the in-market / near-market focus will be the cleanest read on whether deployable cash converts to action this year.

Sources

  1. Viatris Q1 2026 Earnings Release, filed with SEC: https://www.sec.gov/Archives/edgar/data/1792044/000179204426000025/exhibit991-1q26earningsrel.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.